Curaleaf International Wins TGA Approval for Cannabis Inhalation Device in Australia
Curaleaf clears Australian regulatory hurdle for inhaled cannabis product as TGA continues medicinal cannabis approvals.
FILE — statehouse · B.D. Gilfry / CC BY-SA 2.0Curaleaf International has secured Therapeutic Goods Administration (TGA) approval for a cannabis inhalation device in Australia, according to a report from The Manila Times. The approval represents another step in the regulatory expansion of medicinal cannabis delivery formats in the country.
The clearance occurs amid broader Australian regulatory momentum. Recent coverage shows TGA decisions advancing on multiple fronts—including Promethean BioPharma's pain tablet nearing approval and Canopy Growth expanding medical formats and formulations. Federation TAFE has also launched the country's first medicinal cannabis cultivation course, signaling institutional backing for the sector's development.
The device approval suggests regulators are willing to broaden delivery mechanisms beyond traditional formats. Watch whether this clears the path for other companies to seek inhalation-device approvals, and how TGA continues calibrating its "closed-loop" prescribing framework announced in September.
Original report: The Manila Times ↗